Morgan Stanley’s $124 target on BMRN

BMRN BioMarin Pharmaceutical

$65.2 → $124 (+90%) by Aug 2027

Overweight · reiterates · said Aug 31, 2026 · 12-month default horizon

Open: judged on the close on Aug 31, 2027

The article this target came from

Morgan Stanley reiterates BioMarin stock rating on settlement value

Investing.com · Aug 31, 2026

Morgan Stanley reiterated an Overweight stock rating on BioMarin Pharmaceutical Inc. with a price target of $124.00, following a settlement agreement with Ascendis.

Morgan Stanley’s track record → BioMarin Pharmaceutical →

A fact about what Morgan Stanley published, as reported by Investing.com, not a recommendation from Dalsna Finance; Morgan Stanley is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.